Rob

N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo

N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT. Our results demonstrate that DMT administration activates the main adult neurogenic niche, the subgranular zone of the dentate gyrus of […]

N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo Read More »

Western and ketogenic diets in neurological disorders: can you tell the difference?

The prevalence of obesity tripled worldwide between 1975 and 2016, and it is projected that half of the US population will be overweight by 2030. The obesity pandemic is attributed, in part, to the increasing consumption of the high-fat, high-carbohydrate Western diet, which predisposes to the development of the metabolic syndrome and correlates with decreased

Western and ketogenic diets in neurological disorders: can you tell the difference? Read More »

Good bacteria, oxidative stress and neurological disorders: Possible therapeutical considerations

Although oxidative agents such as free radicals can fight pathogens, an imbalance of oxidants to anti-oxidant activity can lead to harmful effects in our body known as oxidative stress. Various cellular organelles produce oxidative agents as well as anti-oxidants. The main oxidative stressors are classified under the free radical species; reactive oxygen species and reactive

Good bacteria, oxidative stress and neurological disorders: Possible therapeutical considerations Read More »

Relationship between risk and protective factors and clinical features of Parkinson’s disease

Risk and protective factors of PD development may influence PD clinical features. This finding may represent the first step in the development of new preventive approaches able to delay disease onset and mitigate the extent of clinical manifestations. CLICK TO REVIEW

Relationship between risk and protective factors and clinical features of Parkinson’s disease Read More »

A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer’s Disease Studies

Alzheimer’s disease (AD) is a global public health priority as with aging populations, its prevalence is expected to rise even further in the future. The brain and gut are in close communication through immunological, nervous and hormonal routes, and therefore, probiotics are examined as an option to influence AD hallmarks, such as plaques, tangles, and

A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer’s Disease Studies Read More »

Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway

Hyperbaric oxygen therapy (HBOT) has been suggested as a potential adjunctive therapy for Parkinson’s disease (PD). PD is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The aim of this study was to investigate the protective mechanisms of HBOT on neurons and motor function in

Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway Read More »

Proof of Concept Study of Prebiotics to Modulate Gut Microbiome in Parkinson’s Disease

Consumption of a novel prebiotic mixture rapidly impacted the intestinal microbiota (10 days), reduced the abundance of pro-inflammatory bacteria and promoted the growth of beneficial SCFA-producing bacteria. In addition, prebiotic consumption increased plasma SCFA levels, and improved markers of intestinal barrier integrity and brain health. This proof-of-concept study provides evidence for the importance of intestinal

Proof of Concept Study of Prebiotics to Modulate Gut Microbiome in Parkinson’s Disease Read More »

Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease

Alpha-synucleinopathy is postulated to be central to both idiopathic rapid eye movement sleep behaviour disorder (iRBD) and Parkinson’s disease (PD). Growing evidence suggests an association between the diminished clearance of α-synuclein and glymphatic system dysfunction. However, evidence accumulating primarily based on clinical data to support glymphatic system dysfunction in patients with iRBD and PD is

Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease Read More »

Quantitative and correlational analysis of gut-brain axis in
schizophrenia spectrum and mood disorders

The pathophysiology of schizophrenia spectrum disorders and associated mood disordersis complex and highly heterogeneous, suggesting that different molecular pathways are involvedin it. Among those, the microbiome and its connection to the brain (“gut-brain axis”) has emergedas a highly promising research avenue. To evaluate the role of the human microbiome in the gutbrain axis, we evaluated

Quantitative and correlational analysis of gut-brain axis in
schizophrenia spectrum and mood disorders
Read More »

Metabolites from the Gut Microbiota and the Role in the
Gut-Brain Axis

The gut microbiota is highly capable of biotransformation, exposing the host to a wide varietyof physiologically active compounds. These metabolites participate in signaling between thegastrointestinal tract and the central nervous system and may regulate physiological andpathological processes in the central nervous system. This bidirectional communication cantake place in a variety of ways, including binding to

Metabolites from the Gut Microbiota and the Role in the
Gut-Brain Axis
Read More »